Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Breast Neoplasms 1

Interventions

pembrolizumab 3atezolizumab 2trametinib 1sargramostim 1ruxolitinib 1reolysin 1poly(I).poly(c12,U) 1poly ICLC 1neratinib 1incomplete Freund's adjuvant 1glembatumumab vedotin 1epigallocatechin gallate 1entinostat 1dupilumab 1Zymosan 1Zinc 1Watchful Waiting 1Vaccines 1Uridine Monophosphate 1Trastuzumab 1Technetium Tc 99m Sestamibi 1Taxes 1Quercetin 1Positron-Emission Tomography 1Paclitaxel 1Neurofibromin 2 1Neoadjuvant Therapy 1Metformin 1Leukapheresis 1Letrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Triple Negative Breast Neoplasms × entinostat × Clear all
NCT03361800 2024-03-25

Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC

UNC Lineberger Comprehensive Cancer Center

Phase EARLY_PHASE1 Terminated
5 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡